ReviewJournal of the American Heart Association2026
From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease.
Sudesh Prajapathi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.